Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Methylation of Human Papillomavirus (HPV) and Cervical Cancer Risk

HPV capsid
Cancer Moonshot: HPV Vaccine Trial & Accelerated Cervical Cancer Control

DCEG researchers are testing one-dose HPV vaccines and creating new screening approaches.

We are examining the methylation of the HPV viral genome in relation to risk of cervical intraepithelial neoplasia 3 (CIN 3) and cancer in specimens accumulated in cohort and case-control studies. As a general rule for multiple HPV types, increased methylation particularly of CpG sites in the L1 gene is strongly associated with increased risk of CIN 3 and cancer. The goal is to understand the etiologic meaning and possible biomarker utility of viral (and cervical) gene methylation for the prevention of cancer. This is a Cancer Moonshot priority.

For more information, contact Mark Schiffman and Nicolas Wentzensen.

Clinical Epidemiology Unit - Research Areas

Email